Fosamax Plus patent doesn't belong to patent scope of Maxmarvil, Intellectual Property Tribunal says

The Korea Intellectual Property Tribunal rejected Yuyu Pharm's request to confirm whether MSD Korea's Fosamax Plus (70 mg alendronate/5,600 IU vitamin D3) is not in the patent scope of Yuyu's Maxmarvil (Korean Patent No. 317935).

The tribunal said in its ruling on June 5, 2006 that Yuyu's patent was well known at the time of its application in 1999, adding that any comparison with Fosamax Pl...